John C Byrd Selected Research

Renal Dialysis (Hemodialysis)

5/2015	Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
1/2014	Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.
7/2010	Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
12/2009	Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
11/2007	Flavopiridol in the treatment of chronic lymphocytic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John C Byrd Research Topics

Disease

238	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 05/2024 - 02/2002
181	Neoplasms (Cancer) 01/2024 - 02/2002
69	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2024 - 01/2004
52	Leukemia 10/2023 - 02/2002
32	Lymphoma (Lymphomas) 01/2021 - 04/2003
23	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2023 - 02/2002
21	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 11/2022 - 01/2009
19	Hematologic Neoplasms (Hematological Malignancy) 10/2023 - 09/2003
18	Disease Progression 01/2022 - 04/2004
14	Infections 01/2023 - 04/2002
14	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 04/2007
13	Multiple Myeloma 01/2019 - 05/2008
12	Atrial Fibrillation 01/2024 - 03/2015
12	B-Cell Lymphoma (Lymphoma, B Cell) 11/2022 - 08/2003
12	Tumor Lysis Syndrome 10/2020 - 08/2003
11	Hemorrhage 07/2023 - 01/2015
11	Diarrhea 01/2023 - 07/2010
10	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 01/2003
9	Hypertension (High Blood Pressure) 01/2024 - 12/2018
9	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2020 - 04/2008
8	Fatigue 12/2019 - 09/2011
8	Breast Neoplasms (Breast Cancer) 01/2018 - 01/2013
8	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2014 - 05/2005
7	Lymphocytosis 01/2023 - 03/2014
7	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021 - 03/2009
7	Neutropenia 01/2020 - 07/2010
7	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 05/2016 - 04/2008
6	Lymphadenopathy 01/2023 - 01/2009
6	Residual Neoplasm 11/2022 - 03/2004
5	Nausea 12/2019 - 01/2003
4	Cytokine Release Syndrome 10/2023 - 01/2009
4	B-Cell Leukemia (Leukemia, B Cell) 01/2021 - 10/2007
4	Cytopenia 01/2020 - 02/2014
4	Lymphoid Leukemia 04/2017 - 01/2004
4	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2016 - 04/2005
4	Agammaglobulinemia (Hypogammaglobulinemia) 01/2016 - 04/2002
4	Thrombocytopenia (Thrombopenia) 01/2015 - 07/2010
4	Fever (Fevers) 07/2014 - 09/2002
4	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 11/2013 - 02/2004
3	Waldenstrom Macroglobulinemia (Macroglobulinemia) 11/2023 - 04/2003

Drug/Important Bio-Agent (IBA)

89	ibrutinibIBA 05/2024 - 06/2011
49	Agammaglobulinaemia Tyrosine KinaseIBA 05/2024 - 06/2011
43	Rituximab (Mabthera)FDA Link 04/2024 - 02/2002
38	Proteins (Proteins, Gene)FDA Link 06/2023 - 01/2003
28	alvocidib (flavopiridol)IBA 06/2016 - 06/2005
27	fludarabineIBA 05/2015 - 02/2002
23	acalabrutinibIBA 05/2024 - 01/2016
18	Lenalidomide (CC 5013)FDA Link 12/2020 - 05/2008
16	Monoclonal AntibodiesIBA 01/2020 - 02/2002
12	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 12/2005
11	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 02/2005
11	Decitabine FDA Link 01/2023 - 07/2005
11	MicroRNAs (MicroRNA)IBA 01/2018 - 06/2009
11	Histones (Histone)IBA 01/2016 - 07/2003
10	Phosphotransferases (Kinase)IBA 12/2022 - 05/2005
10	Cyclin-Dependent Kinases (cdk Proteins)IBA 04/2016 - 01/2007
9	RNA (Ribonucleic Acid)IBA 05/2024 - 06/2009
9	CytokinesIBA 10/2023 - 02/2011
9	venetoclaxIBA 11/2022 - 10/2018
9	Cytarabine (Cytosar-U)FDA LinkGeneric 12/2020 - 01/2003
9	Bortezomib (Velcade)FDA Link 01/2020 - 09/2006
9	Immunoglobulins (Immunoglobulin)IBA 04/2016 - 02/2004
9	Fingolimod Hydrochloride (FTY720)FDA Link 09/2015 - 09/2007
8	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 04/2024 - 08/2004
8	AntigensIBA 10/2023 - 03/2004
8	AntibodiesIBA 10/2022 - 08/2007
8	idelalisibIBA 11/2019 - 09/2010
8	Pentostatin (Nipent)FDA LinkGeneric 01/2015 - 04/2005
8	Alemtuzumab (Campath)FDA Link 12/2013 - 07/2003
7	obinutuzumabIBA 01/2022 - 01/2016
7	Interleukin-2 (IL2)IBA 12/2016 - 09/2004
6	interleukin-21 (interleukin 21)IBA 01/2020 - 05/2008
6	Imatinib Mesylate (Gleevec)FDA Link 12/2014 - 05/2005
5	OSU-2SIBA 01/2022 - 06/2011
5	Histone Deacetylases (Histone Deacetylase)IBA 01/2021 - 07/2003
5	Biomarkers (Surrogate Marker)IBA 01/2019 - 12/2007
5	ofatumumab FDA Link 12/2018 - 03/2013
5	Histone Deacetylase InhibitorsIBA 10/2017 - 01/2004
5	Messenger RNA (mRNA)IBA 04/2017 - 08/2007
5	milatuzumabIBA 06/2015 - 04/2011
5	MethyltransferasesIBA 06/2009 - 02/2005
4	ChromatinIBA 06/2023 - 01/2011
4	Chlorambucil (Leukeran)FDA Link 01/2022 - 05/2006
4	Long Noncoding RNAIBA 01/2022 - 12/2014
4	EnzymesIBA 01/2021 - 04/2004
4	mouse MIRN29 microRNAIBA 01/2019 - 06/2009
4	Immunoglobulin G (IgG)IBA 04/2016 - 02/2004
4	OligodeoxyribonucleotidesIBA 06/2015 - 04/2008
4	Antisense OligonucleotidesIBA 06/2015 - 01/2003
4	OligonucleotidesIBA 01/2013 - 06/2009
4	NF-kappa B (NF-kB)IBA 07/2010 - 02/2008
4	Complement System Proteins (Complement)IBA 01/2008 - 02/2002
4	CaspasesIBA 03/2005 - 02/2002
3	Bendamustine Hydrochloride FDA Link 04/2024 - 01/2015

Therapy/Procedure

155	Therapeutics 04/2024 - 04/2002
37	Drug Therapy (Chemotherapy) 11/2023 - 02/2002
8	Immunotherapy 10/2023 - 09/2004
6	Aftercare (After-Treatment) 01/2023 - 02/2002
5	Renal Dialysis (Hemodialysis) 05/2015 - 11/2007
4	Stem Cell Transplantation 01/2020 - 01/2006